바카라
바카라 KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDxTMIN JAPAN
2023/12/15바카라 Kayaku Co., Ltd. (Head Office: Tokyo; President: Mr. Atsuhiro Wakumoto; hereinafter "바카라 Kayaku") and BioCheetah Pte. Ltd. (Head Office: Singapore; CEO: Dr. Lee Kian Chung; hereinafter "BioCheetah") announce that the two companies have entered into a licensing agreement for the exclusive rights to develop and market in Japan a novel urinary bladder cancer diagnostic marker assay kit, VECanDxTMELISA (hereinafter "Product"), which BioCheetah develops in Singapore with 바카라 aim of obtaining regulatory approval as an in vitro diagnostic product.
1. Outline of 바카라 Agreement
Under the agreement, 바카라 Kayaku will obtain from BioCheetah the exclusive rights to develop and market the Product in Japan. BioCheetah will continue to complete clinical trials in Singapore, France and China, while 바카라 Kayaku will be responsible for clinical trials, regulatory application, distribution, sales, promotion, etc. of Product in Japan. 바카라 Kayaku will pay an upfront payment upon signing the agreement, as well as milestone payments based on the commercialization of the Product in Japan to BioCheetah.
2. About VECanDxTM
This in vitro diagnostic candidate uses ELISA (Enzyme-Linked Immuno Sorbent Assay) as its measurement principle to measure five biomarkers that BioCheetah has newly discovered in urine of bladder cancer patients. 바카라 measured values of each biomarker are assigned to Product's dedicated software to calculate a risk score and detect bladder cancer.
3. Outline of BioCheetah Pte. Ltd.
1) Business Name ： BioCheetah Pte. Ltd.
2) Head Office Address ： 79 Ayer Rajah Crescent, #05-09, Singapore 139955
3) Representative ： Dr. Lee Kian Chung, CEO
4) Foundation ： 2018
5) Business Activities ： Search for new biomarkers and research, development and marketing of non-invasive testing methods, etc.
6) Relationship with 바카라 Kayaku ： Capital relationship, personal relationship, business relationship, and related party status: None
4. About BioCheetah
BioCheetah is a Singapore-based, A*STAR-IMCB spin-off diagnostics company. It is primarily set up to develop and commercialize non-invasive, protein-based immunodiagnostic applications. 바카라y are currently developing ELISA and POCT kits for 바카라 discovered markers.
5. Future Outlook
바카라 impact of this agreement on our consolidated business results for 바카라 fiscal year ending March 31, 2024 is expected to be insignificant. We believe that it will contribute to improving our business performance and corporate value in 바카라 medium to long term.
[Contact]
바카라 Kayaku Co., Ltd., Corporate Communications Division
TEL: +81-3-6731-5237
